MX2017006270A - Compuestos de 1,2-benzotiazol para el tratamiento de transtornos renales. - Google Patents

Compuestos de 1,2-benzotiazol para el tratamiento de transtornos renales.

Info

Publication number
MX2017006270A
MX2017006270A MX2017006270A MX2017006270A MX2017006270A MX 2017006270 A MX2017006270 A MX 2017006270A MX 2017006270 A MX2017006270 A MX 2017006270A MX 2017006270 A MX2017006270 A MX 2017006270A MX 2017006270 A MX2017006270 A MX 2017006270A
Authority
MX
Mexico
Prior art keywords
treatment
kidney disorders
benzothiazole compounds
benzothiazole
disorders
Prior art date
Application number
MX2017006270A
Other languages
English (en)
Inventor
James Genin Michael
Glen Holloway William
David Rekhter Mark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017006270A publication Critical patent/MX2017006270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención proporciona compuestos de 1,2-benzotiazol particularmente útiles en el tratamiento de la nefropatía diabética y otros trastornos renales crónicos y otras complicaciones diabéticas.
MX2017006270A 2014-11-21 2015-11-13 Compuestos de 1,2-benzotiazol para el tratamiento de transtornos renales. MX2017006270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082655P 2014-11-21 2014-11-21
PCT/US2015/060635 WO2016081311A1 (en) 2014-11-21 2015-11-13 1,2-benzothiazole compounds for the treatment of kidney disorders

Publications (1)

Publication Number Publication Date
MX2017006270A true MX2017006270A (es) 2017-08-14

Family

ID=54705861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006270A MX2017006270A (es) 2014-11-21 2015-11-13 Compuestos de 1,2-benzotiazol para el tratamiento de transtornos renales.

Country Status (12)

Country Link
US (1) US20170246166A1 (es)
EP (1) EP3221310A1 (es)
JP (1) JP2017531684A (es)
KR (1) KR20170068587A (es)
CN (1) CN107074842A (es)
AU (1) AU2015350252A1 (es)
BR (1) BR112017007112A2 (es)
CA (1) CA2963683A1 (es)
EA (1) EA201790868A1 (es)
MX (1) MX2017006270A (es)
NZ (1) NZ730759A (es)
WO (1) WO2016081311A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195321B1 (en) * 2007-04-12 2016-10-19 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
WO2013037390A1 (en) * 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102993201A (zh) * 2011-09-14 2013-03-27 赛诺菲 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3，4-b]吡啶-4-羧酸酰胺衍生物

Also Published As

Publication number Publication date
JP2017531684A (ja) 2017-10-26
US20170246166A1 (en) 2017-08-31
EA201790868A1 (ru) 2017-10-31
KR20170068587A (ko) 2017-06-19
BR112017007112A2 (pt) 2017-12-26
CN107074842A (zh) 2017-08-18
EP3221310A1 (en) 2017-09-27
NZ730759A (en) 2018-10-26
WO2016081311A1 (en) 2016-05-26
AU2015350252A1 (en) 2017-05-04
CA2963683A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
MY197345A (en) Antibody molecules to april and uses thereof
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EP3122872A4 (en) Compositions and methods for treating type 1 and type 2 diabetes and related disorders
AU2017277478A1 (en) Pharmaceutical combinations for treating cancer
IL251880A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3710010A4 (en) USE OF HM4DI IN TREATMENT OF SEQUENCE DISEASES
IL256413B (en) IL-8 inhibitors for use in the treatment of certain urological disorders
NZ730759A (en) 1,2-benzothiazole compounds for the treatment of kidney disorders
HK1244288A1 (zh) 用於治療CNS病症的3α-乙炔基，3β-羥基-5α-孕甾烷-20-肟
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci